ASND241018P140000
- 12.45
- 0.000.00%
Ascendis Pharma A/S Newsroom
Ascendis Pharma Is Maintained at Buy by TD Cowen
Ascendis Pharma Analyst Ratings
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
TD Cowen Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $160
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
Ascendis Pharma Analyst Ratings
B of A Securities Maintains Buy on Ascendis Pharma, Raises Price Target to $191
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Hold Rating, Maintains Target Price $167
BofA Securities Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $191
Cantor Fitzgerald Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $205
J.P. Morgan Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $180
Oppenheimer Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $190
Ascendis Pharma Analyst Ratings
Ascendis Pharma Is Maintained at Buy by Citigroup
Jefferies Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $179
Ascendis Pharma Is Maintained at Outperform by Evercore ISI Group
Goldman Sachs Maintains Buy on Ascendis Pharma, Raises Price Target to $200
A Quick Look at Today's Ratings for Ascendis Pharma A/S(ASND.US), With a Forecast Between $175 to $289